Genomenon Series B Press Release FAQ

1. **Why was Genomenon founded?**

   Genomenon's mission is to save and improve lives by making genomic information actionable. Next-generation sequencing (NGS) provides the ability to rapidly and cost-effectively sequence patients' entire genome – creating terabytes of data in the process. The challenge now is making sense of all the data that comes from sequencing. Genomenon was founded to make genomic information actionable to help clinicians rapidly diagnose patients suffering from rare diseases to cancer and to help researchers create precision medicines targeted at the molecular drivers of these diseases.

2. **What market need does the company fill?**

   Clinical diagnoses are rooted in the medical evidence found in peer-reviewed scientific journals. The challenge for clinicians and researchers is finding the scientific evidence that connects genomic variants to diseases to make a diagnosis. It's extremely difficult and time-consuming to scour the internet for scientific papers when authors describe variants in hundreds of different ways – like finding a needle in a haystack.

   Genomenon's AI engine indexes and organizes the world's scientific literature to find every needle in every haystack and put it at the fingertips of clinicians to diagnose patients, and researchers to develop precision medicines.

   Genomenon's *Mastermind® Genomic Search Engine* is the de facto market leader in genomic search – used by more than 1,000 genetic testing labs around the world to aid in the diagnosis of rare disease and cancer patients. Genomenon's *Prodigy Genomic Landscapes™* are used by pharma and biopharma researchers to identify critical genomic biomarkers to match patients to clinical trials, and inform drug discovery and development.

3. **Can you describe the company's core technology and competitive advantages?**

   The *Mastermind Genomic Search Engine* uses Genomic Language Processing (GLP) to identify every genomic association from the peer-reviewed medical evidence to draw informative connections between genes, variants, copy number variants (CNVs), diseases,

phenotypes, and therapies to inform both clinical care and drug discovery. By allowing users to find, connect, explore, and understand the genomic links to diseases, Mastermind elevates the efficiency and accuracy of the clinical decision-making process.

Genomenon's AI-driven *Prodigy Genomic Landscapes* deliver a profound understanding of the genetic drivers and clinical attributes of any genetic disease, from neurodegenerative and rare diseases to cancer. This data enables pharmaceutical companies to accelerate target discovery, identify genetic biomarkers for better clinical trial stratification, and develop companion diagnostics for regulatory approval.

Genomenon's differentiators: the breadth of its content, the depth to which the company understands that content, and the sophistication with which it surfaces that information when needed. Genomenon delivers the most comprehensive understanding of genomics in the market by indexing 100 times more content and finding over 40 times more genomic variants than the largest manually curated database.

4. How was the Series A funding used? What are some of the company's recent milestones?

The Series A proceeds were used to expand Genomenon's commercial operations, which serve genetic testing labs, hospitals, pharmaceutical and biopharma companies. The company also recruited top scientific and commercial talent, and accelerated R&D for its Mastermind Genomic Search Engine.

Recent milestones include:

- Partnerships with Inozyme Pharma and Alexion/AstraZeneca Rare Disease.
- A $1.7 million grant from the National Institutes of Health (NIH) through the Small Business Innovation Research (SBIR) program. The grant is to accelerate development of the Mastermind Genomic Search Engine, the company's AI-driven variant interpretation engine, with a vision of curating the entire human genome.
- Genomenon was named Global Company of the Year in Clinical Genomics Interpretation by Frost & Sullivan.

5. What will the new Series B funds be used for?

Genomenon will use the proceeds from the Series B financing to expand its commercial operations and the development of its genomic data hub which serves genetic testing labs, hospitals, pharmaceutical and biopharma companies.

6. Who participated in the investment round?

The $20 million Series B financing round was led by Beringea and Spring Mountain Capital and included participation from BroadOak Capital and Riverine Ventures joining as new investors in the company. The financing was also supported by the company's current

investors, including Green Park & Golf Ventures, the University of Michigan, IrishAngels, Red Cedar Ventures, Michigan Rise, Invest Detroit Ventures, Michigan Angel Fund and Atain Specialty Insurance Company.

7. Why did these firms invest in Genomenon?

Beringea invests in emerging industries and technologies including data and AI, and believes Genomenon offers a compelling value proposition and visionary leadership—key advantages that will accelerate clinical decision-making and pharmaceutical drug discovery.

Spring Mountain Capital focuses on alternative asset investing, partnering with world-class management teams that build the businesses of the future. Genomenon was an outstanding investment due to its proven leadership team and disruptive technology platform.

BroadOak Capital Partners is a leading investor in the research tools, diagnostics, and biopharma services industries.

8. What's next for Genomenon?

Genomenon will expand its commercial operations and the development of its genomic data hub, which serves genetic testing labs, hospitals, pharmaceuticals and biopharma companies. It will continue to evolve its AI-driven genomic engine, and incorporate features for community-based variant interpretation. The company is curating the human genome for meaning and actionability at scale to improve patient care and precision medicine.